The results demonstrated that the combination treatment resulted in reduced tumour growth and improved survival relative to injection of either drug alone, further confirming the usefulness of HSV1716/NAT for gene therapy and targeted radionuclide therapy performed on cancers. Here, BRD2 is linked to neoplasm.